A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Developers like Vertex, Regeneron and Novo Nordisk have significantly upped R&D spending in recent years, and become important acquirers.
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.
Pfizer’s buying spree propels it up the rankings, while Lilly continues to turn (relatively) small spend into big value.
Neither route to the stock market covered itself in glory in the recent bull market. But how do returns really stack up?
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?